Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Nimesh Goel
AddedMar 31, 2024
UpdatedMay 31, 2026
Nimesh Goel

Nimesh Goel

Founder & CEO, ChillHit Labs

CrunchbaseLinkedIn

Nimesh Goel's Career

ChillHit Labs
ChillHit Labs

San Diego, CA, US

Founder & CEO· C-Suite · Management
Batu Biologics
Batu Biologics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Nimesh Goel's Career

ChillHit Labs
ChillHit Labs
Seed$200k302015San Diego, CA, US
Founder & CEO· C-Suite · Management

Similar to ChillHit Labs

Hemp Hunter LabsHemp Hunter LabsMiami, FL, USCBD Products, Hemp Extractsest. 2018Hemp Hunter LabsMiami, FL, US · est. 2018

Hemp Hunter Labs: Expert formulator and processor of CBD-infused products and hemp extracts since 2018.

Angel · $50k6
Mile High LabsMile High LabsLoveland, CO, USCBD, CBD Productsest. 2016Mile High LabsLoveland, CO, US · est. 2016

Mile High Labs: Premium CBD production, refining, and co-packing services under GMP certification.

Series B · $122.8M63
Cresco LabsCresco LabsChicago, IL, USCannabis, Productsest. 2013Cresco LabsChicago, IL, US · est. 2013

Cresco Labs: Chicago-based cultivator and processor of precision-dosed medical cannabis products.

Public · $540.5M3.2k
Out & About CBDOut & About CBDSan Juan Capistrano, CA, USCBD Products, Wellness Servicesest. 2019Out & About CBDSan Juan Capistrano, CA, US · est. 2019

Out & About CBD offers top-quality wellness services and hemp CBD products, enhancing LGBT community's well-being.

Seed · $1.6M6
Batu Biologics
Batu Biologics
Pre-Seed$2.8M62013San Diego, CA, US
Board Member· Board

Leadership at Batu Biologics

Alan LewisAlan LewisBoard Member
Thomas E IchimThomas E IchimCEO
Vladimir BoginVladimir BoginBoard Member
Dr John ChiplinDr John ChiplinBoard Member

Similar to Batu Biologics

Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
ImmuneBridgeImmuneBridgeSan Francisco, CA, USCancer Therapiesest. 2018ImmuneBridgeSan Francisco, CA, US · est. 2018

ImmuneBridge pioneers in developing allogeneic immunotherapies for cancer using cord blood-derived stem cells.

Seed · $12M16
Immpact BioImmpact BioCamarillo, CA, USCAR T-Cell Therapyest. 2017Immpact BioCamarillo, CA, US · est. 2017

ImmPACT Bio: Innovating transformative CAR-T cell therapies for advanced cancer patients.

Series B · $129M105
Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39

Nimesh Goel's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Nimesh Goel

Aakash SudhakarAakash SudhakarCEO · ChillMatt RogersMatt RogersCo-Founder · Incite.orgDavid KleinDavid KleinCEO · DHK StorageJohn DeedrickJohn DeedrickBoard Member · ActivOrthoAleks BochkovAleks BochkovCo-Founder · NoplagNeil SahotaNeil SahotaBoard Member · Otomo